ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?

被引：1
|
作者：
Kumar, Naveen [1 ]
机构：
[1] Medanta Hosp, Dept Urol, Patna, Bihar, India
来源：
INDIAN JOURNAL OF UROLOGY | 2022年 / 38卷 / 03期
关键词：
D O I：
10.4103/iju.iju_81_22
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
  • [31] EFFICACY AND FEASIBILITY OF ADDITIONAL CYCLES OF DOCETAXEL IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF UROLOGY, 2023, 209 : E388 - E389
  • [32] Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
    Guo, Zhuifeng
    Lu, Xuwei
    Yang, Fan
    Qin, Liang
    Yang, Ning
    Wu, Jiawen
    Wang, Hang
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [33] RAPID, DURABLE, AND DEEP PROSTATE-SPECIFIC ANTIGEN RESPONSE FOLLOWING ADDITION OF DAROLUTAMIDE TO ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN ARASENS
    Saad, Fred
    Tombal, Bertrand
    Hussain, Maha
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Nordquist, Luke T.
    Tutrone, Ronald
    Shore, Neal D.
    Belkoff, Laurence
    Kapur, Shivani
    Jhaveri, Jay
    Ortiz, Jorge
    Srinivasan, Shankar
    Verholen, Frank
    Smith, Matthew R.
    JOURNAL OF UROLOGY, 2023, 209 : E380 - E380
  • [34] Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
    Kretschmer, Alexander
    Todenhoefer, Tilman
    EUROPEAN UROLOGY FOCUS, 2019, 5 (02): : 114 - 116
  • [35] Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
    Tucci, Marcello
    Bertaglia, Valentina
    Vignani, Francesca
    Buttigliero, Consuelo
    Fiori, Cristian
    Porpiglia, Francesco
    Scagliotti, Giorgio Vittorio
    Di Maio, Massimo
    EUROPEAN UROLOGY, 2016, 69 (04) : 563 - 573
  • [36] Rate of hospitalization and length of hospital stay during and post docetaxel for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS.
    Morgans, Alicia K.
    Boegemann, Martin
    Paracha, Noman
    Grossman, Jamie
    Santamaria, Fernando Rodriguez
    Tyas, Emma
    Candish, Jane
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 228 - 228
  • [37] Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review
    Raval, Amit D.
    Chen, Stephanie
    Littleton, Natasha
    Constantinovici, Niculae
    Goebell, Peter J.
    BJU INTERNATIONAL, 2025, 135 (03) : 408 - 421
  • [38] Darolutamide (DARO) in combination with androgendeprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III ARASENS study
    Wang, S.
    Fu, C.
    Li, Y.
    Xing, J.
    Zhou, L.
    Yang, Y.
    Wang, H.
    Smith, M. R.
    Tombal, B.
    Hussain, M.
    Niu, Y.
    Cai, L.
    Liu, Q.
    Littleton, N.
    Li, R.
    Ye, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1572 - S1572
  • [39] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
    Lee, Arnold
    TARGETED ONCOLOGY, 2023, 18 (05) : 793 - 800
  • [40] Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial
    Burgess, Earle F.
    Grigg, Claud M.
    Boselli, Danielle
    Symanowski, James T.
    Golshayan, Alireza
    Graham, David L.
    Osei-Boateng, Kwabena
    Gavini, Nagajyothi
    Zhu, Jiang
    Brown, Landon C.
    Norek, Sarah
    Begic, Xhevahire J.
    Raghavan, Derek
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
12345